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as high-risk group with total scores 2–3 points. The 
median overall survival for low-risk group and high-risk 
group was 9.9 months (95 % CI 6.8–13.0) and 5.3 months 
(95 % CI 4.1–6.5), respectively (hazard ratio 0.27; 95 % 
CI 0.14–0.52; P < 0.001). The estimated 1-year survival 
rates for low-risk group and high-risk group were 40.5 and 
5.9 %, respectively (P < 0.05).
Conclusions A novel prognostic index model based on 
three clinical parameters was established to predict the 
prognosis of patients with advanced pancreatic cancer 
receiving palliative chemotherapy.
Keywords Advanced pancreatic cancer · Prognostic 
index model · Palliative chemotherapy
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Abstract 
Purpose To establish a prognostic index model for 
advanced pancreatic cancer patients receiving palliative 
chemotherapy based on clinical variables.
Methods The clinical data of 118 patients with advanced 
pancreatic cancer who received palliative chemotherapy 
between January 2006 and August 2013 in our center were 
retrospectively analyzed. Prognostic factors for overall 
survival were identified using Cox proportional hazards 
model. A prognostic index model was established by these 
pretreatment factors to predict prognosis. Kaplan–Meier 
estimation and log-rank test were performed to compare 
the overall survival difference between low-risk and high-
risk group of patients.
Results Median overall survival time for all patients 
was 8.8 months [95 % confidence interval (CI) 7.0–
10.6 months]. Multivariate analysis identified ECOG 
score = 2 (hazard ratio 2.03; 95 % CI 1.07–3.85; 
P = 0.030), CA19-9 levels of ≥1000 U/mL (hazard 
ratio 2.07; 95 % CI 1.09–3.92; P = 0.026), and CRP lev-
els of ≥5 mg/L (hazard ratio 2.05; 95 % CI 1.06–3.96; 
P = 0.033) as independent poor prognostic factors for 
overall survival. For the three factors, ECOG score = 2, 
CA19-9 levels of ≥1000 U/mL, and CRP levels of 
≥5 mg/L were allocated 1 point each. There were 84 
(71.2 %) patients allocated to low-risk group with total 
score 0–1 point, and 34 (28.8 %) patients were categorized 
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Introduction
Pancreatic cancer is a devastating malignant disease repre-
sented by almost equal morbidity and mortality annually 
(Siegel et al. 2013). It is estimated to be the second leading 
cause of cancer-related death in USA around 2020 (Rahib 
et al. 2014). Although surgical resection is the only poten-
tial curative modality, only 10–20 % of patients were first 
diagnosed with resectable tumor (Heinemann et al. 2012). 
Even after curative resection, a large proportion of patients 
develop recurrence within 1 year (Katz et al. 2009; Baru-
gola et al. 2009). The 5-year survival rate remains dismal 
(Stathis and Moore 2010).
In clinical practice, most patients present with locally 
advanced or metastatic disease at the first diagnosis 
(Heinemann et al. 2012; Stathis and Moore 2010). Pallia-
tive chemotherapy with gemcitabine (Burris et al. 1997; 
Heinemann et al. 2008) or S-1 (Okusaka et al. 2008; Ueno 
et al. 2013) based regimen for advanced pancreatic can-
cer (APC) has been established as the standard of care in 
recent years. However, the prognosis of patients receiv-
ing palliative chemotherapy varies depending on a num-
ber of clinical characteristics (Papadoniou et al. 2008). It 
is crucial to identify the subgroup of APC patients who 
would benefit from palliative chemotherapy (Philip et al. 
2009). Previous studies have identified several prognostic 
factors for survival, such as pretreatment CA19-9 (Saad 
et al. 2002; Reni et al. 2009), C-reactive protein (CRP) 
(Haas et al. 2010; Wang et al. 2012), serum albumin lev-
els (Maréchal et al. 2007), neutrophil-to lymphocyte ratio 
(NLR) (Xue et al. 2014), and performance status (Tas et al. 
2013). However, the predictive value of these factors for 
palliative chemotherapy of APC patients is still controver-
sial. Therefore, the development of an alternative method 
to predict the prognosis for APC patients is attracting more 
attention. Glasgow Prognostic Score (GPS) (McMillan 
2013), a notable prognostic scoring method, which was 
developed a decade ago, represented a sensitive measure 
of the systemic inflammatory response and nutritional 
status of patient. Glen et al. (2006) verified its prognos-
tic value in patients with inoperable pancreatic cancer. 
However, the host-related factor of GPS alone can hardly 
reflect the overall status of patients with pancreatic cancer. 
Therefore, we sought to develop a comprehensive and fea-
sible prognostic index model to predict the prognosis for 
APC patients in daily practice.
In this study, we investigated multiple pretreatment 
variables that are easily accessible in clinical practice 
to predict the outcomes of APC patients receiving pal-
liative chemotherapy. Furthermore, a prognostic index 
model derived from the independent prognostic factors 
was established to effectively identify the high-risk group 
of APC patients undergoing gemcitabine- or S-1-based 
palliative chemotherapy. It could be valuable for clinicians 
in decision making of treatment strategies and assessment 




Clinical data of 145 consecutive APC patients, who 
received gemcitabine- or S-1-based palliative chemo-
therapy in our cancer center between January 2006 and 
August 2013, were retrospectively analyzed. Twenty-
seven cases were excluded from this study due to defi-
cient pathological or clinical data, and 118 patients who 
met the following inclusion criteria were included in our 
study: (1) patients with pathologically confirmed invasive 
ductal carcinoma of the pancreas, either by surgical resec-
tion or needle biopsy; (2) patients presented with locally 
advanced unresectable or metastasis disease diagnosed by 
computed tomography (CT) or magnetic resonance imag-
ing (MRI); and (3) patients with available clinical data at 
the first administration of gemcitabine- and/or S-1-based 
palliative chemotherapy. All patients enrolled had signed 
informed consent previously for the purpose of clinical 
research. This study was approved by the Ethics Com-
mittee of Shanghai General Hospital, Shanghai Jiaotong 
University.
Palliative chemotherapy consisted of gemcitabine- or 
S-1-based regimens, including gemcitabine monotherapy 
(n = 68) (Burris et al. 1997), gemcitabine and cisplatin 
combination therapy (n = 8) (Heinemann et al. 2006), 
gemcitabine and oxaliplatin combination therapy (n = 12) 
(Louvet et al. 2005), gemcitabine and nab-paclitexal com-
bination therapy (n = 4) (Von Hoff et al. 2013), gemcit-
abine and erlotinib combination therapy (n = 4) (Moore 
et al. 2007), and S-1 monotherapy (n = 22) (Okusaka et al. 
2008; Ueno et al. 2013). The specific dosage and schedule 
of each regimen were adjusted by the physicians based on 
the individual patient’s general condition.
Prognostic factors
The integrated clinical data included patients’ demograph-
ics, the medical treatment records, pathological reports, 
tumor-node-metastasis stage, imaging scan of body, and 
pretreatment laboratory data were collected for analy-
sis. Fourteen clinical variables were chosen as potential 
prognostic factors, among which continuous parameters 
were divided into two categories according to the pre-
vious studies (Papadoniou et al. 2008; Haas et al. 2010; 
Xue et al. 2014; Tanaka et al. 2008) for the convenience 
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of prognostic analysis as follows: age (<65 or ≥65 years), 
gender (male or female), Eastern Cooperative Oncology 
Group (ECOG) score (0–1 or 2), primary tumor location 
(head or body/tail), prior tumor resection (no or yes), dis-
tant metastasis (no or yes), levels of carbohydrate antigen 
19-9 (CA19-9 <1000 or ≥1000 U/mL), carcinoembryonic 
antigen (CEA <5 or ≥5 ng/mL), C-reactive protein (CRP 
<5 or ≥5 mg/L), hemoglobin (<100 or ≥100 g/L), neutro-
phil-to-lymphocyte ratio (NLR <5 or ≥5), platelet to lym-
phocyte ratio (PLR <150 or ≥150), and albumin (<35 or 
≥35 g/L).
Statistical analysis
All of the analyses were performed using SPSS statistical 
software (version 17.0, SPSS Inc, Chicago, IL, USA). The 
primary end point of the study was overall survival (OS). 
OS was calculated from the initiation of palliative chemo-
therapy to the date of death for any reason or the last fol-
low-up visit of patient. OS were estimated by the Kaplan–
Meier method, and the difference in OS was compared by 
log-rank tests. Prognostic variables associated with OS 
were identified through univariate analysis by Cox regres-
sion models. The hazard ratio (HR) and 95 % confidence 
interval (CI) were calculated using Cox regression models. 
A two-tailed P value of <0.05 was considered statistically 
significant. The independent prognostic variables asso-
ciated with OS were confirmed by multivariate analysis 
using Cox proportional hazards model. A prognostic index 
model was established based on independent variables that 




A total of 118 consecutive patients with APC treated with 
first-line palliative chemotherapy between January 2006 
and August 2013 were investigated. The median age of 
these patients was 62 years (range 34–82). Seventy-four 
patients (62.7 %) had relatively good general conditions 
with ECOG score 0–1. Forty-six patients (39.0 %) had 
pancreatic head carcinoma, while seventy-two patients 
(61.0 %) had carcinoma in the body and tail of pancreas. 
Twenty-four patients (20.3 %) had received primary pan-
creatic lesion resection before recurrence. Forty-six patients 
(39.0 %) had unresectable locally advanced lesion, while 
seventy-two patients (61.0 %) had distant metastatic dis-
ease. Of these patients, sixty-four (54.2 %) had liver metas-
tasis, sixty (50.8 %) had celiac lymph node metastasis, and 
thirty-four (28.8 %) had ascites or peritoneum metastasis. 
Twenty-two patients (18.6 %) received S-1 monotherapy; 
other ninety-six patients (81.4 %) received gemcitabine-
containing regimen treatment, among which sixty-eight had 
received gemcitabine monotherapy and twenty-eight had 
received gemcitabine-based combination therapy. Patients’ 
baseline characteristics are shown in Table 1.
Univariate and multivariate analysis of prognostic 
factors
Univariate analysis of potential prognostic factors associ-
ated with OS in this cohort showed that ECOG score of 
Table 1  Baseline characteristics of 118 patients with advanced pan-
creatic cancer (APC)
Characteristic Median (range) Number (%)
Age (years) 62 (34–82)
Gender
 Male 86 (72.9)
 Female 32 (27.1)
PS score
 0–1 74 (62.7)
 2 44 (37.3)
Primary tumor location
 Head 46 (39)
 Body and tail 72 (61)
Recurrent or unresectable disease
 Unresectable 74 (79.7)
 Recurrent 24 (20.3)
Metastasis
 Liver 64 (54.2)
 Lymph node 60 (50.8)
 Peritoneum 34 (28.8)
Palliative first-line regimen
 Gemcitabine containing 96 (81.4)
 S-1 containing 22 (18.6)
NLR
 <5 84 (71.2)
 ≥5 34 (28.8)
PLR
 <150 76 (64.4)
 ≥150 42 (35.6)
CA19-9 (U/mL) 601.8 (0.6–2084)
CEA (ng/mL) 34.9 (0.4–770)
CRP (mg/L) 14 (0.2–135)
ALP (IU/L) 163.7 (36–707)
Hemoglobin (g/L) 111 (63–156)
Albumin (g/L) 39.7 (28–48.7)
TB (mg/dL) 15.8 (6–97.9)
AST (IU/L) 32.1 (9–116)
ALT (IU/L) 25.9 (5–101.7)
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2, unresectable disease, distant metastasis, CA19-9 levels 
of ≥1000 U/mL, CRP levels of ≥5 mg/L, and NLR ≥5 
were significantly associated with poor OS (P < 0.05). 
Performing the subsequent multivariate analysis, a total of 
three factors, including ECOG score = 2, CA19-9 levels of 
≥1000 U/mL, and CRP levels of ≥5 mg/L, were identified 
Table 2  Univariate and multivariate analyses of prognostic factors in APC patients




Univariate analysis Multivariate analysis
Hazard ratio 95 % CI P value Hazard ratio 95 % CI P value
Age (years)
 ≥65 40 (33.9) 8.8 (5.179–12.421) 1 0.632–2.253 0.585
 <65 78 (66.1) 8.5 (5.808–11.192) 1.194
Gender
 Female 32 (27.1) 6.3 (4.144–8.456) 1 0.673–2.777 0.388
 Male 86 (72.9) 8.9 (6.796–11.004) 1.367
ECOG score
 2 44 (37.3) 5.5 (4.351–6.649) 1 0.255–0.863 0.015 1 0.260–0.933 0.030
 0–1 74 (62.7) 9.9 (6.880–12.920) 0.470 0.493
Primary tumor location
 Body and tail 72 (61) 7.3 (5.142–9.458) 1 0.632–2.170 0.617
 Head 46 (39) 8.9 (3.578–14.222) 1.171
Recurrent or unresectable 
disease
 Unresectable 74 (79.7) 6.9 (5.288–8.512) 1 0.165–0.848 0.018 1 0.193–1.107 0.083
 Recurrent 24 (20.3) 13.8 (8.862–18.738) 0.374 0.463
Distant metastasis
 Yes 72 (61) 6.9 (5.430–8.370) 1 0.275–0.972 0.041 1 0.475–1.857 0.856
 No 46 (39) 12.7 (9.336–16.064) 0.517 0.939
CA19-9 (U/mL)
 ≥1000 38 (32.2) 5.3 (4.020–6.580) 1 0.194–0.662 0.001 1 0.255–0.918 0.026
 <1000 80 (67.8) 9.9 (6.689–13.111) 0.359 0.484
CEA (ng/mL)
 ≥5 78 (66.1) 8.8 (6.965–10.635) 1 0.443–1.583 0.585
 <5 40(33.9) 7.2 (0–16.750) 0.837
CRP (mg/L)
 ≥5 54 (45.8) 5.9 (4.373–7.427) 1 0.268–0.890 0.019 1 0.253–0.945 0.033
 <5 64 (54.2) 10.6 (6.576–14.624) 0.488 0.489
Hemoglobin (g/L)
 <100 18 (15.3) 4.5 (3.331–5.669) 1 0.228–1.064 0.072
 ≥100 100 (84.7) 8.9 (6.664–11.136) 0.493
NLR
 ≥5 34 (28.8) 5 (3.118–6.882) 1 0.215–0.786 0.007 1 0.272–1.029 0.061
 <5 84 (71.2) 9 (4.343–13.657) 0.411 0.529
PLR
 ≥150 42 (35.6) 9.7 (8.155–11.245) 1 0.524–1.792 0.919
 <150 76 (64.4) 7.2 (5.086–9.314) 0.969
Albumin (g/L)
 <35 24 (20.3) 6 (2.945–9.055) 1 0.314–1.308 0.222
 ≥35 94 (79.7) 9 (5.496–12.504) 0.641
Regimen
 Gemcitabine containing 96 (81.4) 8.5 (6.657–10.343) 1 0.740–3.260 0.245
 S-1 containing 22 (18.6) 8.9 (1.469–16.331) 1.553
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as independent prognostic factors for poor OS in APC 
patients following palliative chemotherapy (Table 2).
Overall survival
With median follow-up period of 8.5 months (range 0.5–
65.8), 88 patients (74.6 %) were reported dead at time 
of last follow-up. The median OS time for all the 118 
patients was 8.8 months [95 % confidence interval (CI), 
7.0–10.6 months] since initiation of palliative chemother-
apy (Fig. 1). The 1- and 2-year survival rates were 32.2 and 
10.2 %, respectively.
To compare OS of patients with different profiles of 
prognostic factors, we divided patients in subgroups 
according to the independent prognostic factors identi-
fied in the multivariate analysis, including ECOG score, 
CA19-9 levels, and CRP levels, and compared the Kaplan–
Meier curves for OS by log-rank test (Fig. 2). The median 
OS was 5.5 months (95 % CI 4.4–6.6) in ECOG score 2 
group and 9.9 months (95 % CI 6.9–12.9) in ECOG score 
0–1 group [hazard ratio (HR) 0.47; 95 % CI 0.26–0.86; 
P = 0.015]. For patients with CA19-9 levels of ≥1000 
versus <1000 U/mL, median OS was 5.3 months (95 % 
CI 4.0–6.6) versus 9.9 months (95 % CI 6.7–13.1) (HR 
0.36; 95 % CI 0.19–0.66; P = 0.001). The median OS for 
patients with CRP levels ≥5 mg/L was 5.9 months (95 % 
CI 4.4–7.4) compared with 10.6 months (95 % CI 6.6–
14.6) in patients with CRP levels <5 mg/L (HR 0.49; 95 % 
CI 0.27–0.89; P = 0.019).
Prognostic index model
The pretreatment ECOG score, CA19-9 levels, and CRP 
levels identified as independent prognostic factor by multi-
variate analysis were used to establish the prognostic index 
model. Table 3 shows the criteria of prognostic index model 
as follows: ECOG score 2, CA19-9 levels of ≥1000 U/
mL, and CRP levels ≥5 mg/L were allocated 1 point each; 
ECOG score 0–1, CA19-9 levels of <1000 U/mL, and CRP 
levels <5 mg/L were allocated 0 point each. The total score 
ranging from 0 to 3 was categorized into two prognostic 
index risk groups as defined as follows: low-risk group, 
0 or 1 point; high-risk group, 2 or 3 point. There were 
84 (71.2 %) patients allocated to low-risk group, and 34 
(28.8 %) patients were categorized as high-risk group. The 
median OS for the low-risk group was 9.9 months (95 % 
CI 6.8–13.0), which was significantly longer than that of 
5.3 months (95 % CI 4.1–6.5) in high-risk group (HR 0.27; 
95 % CI 0.14–0.52; P < 0.001). The estimated 1-year sur-
vival rates for low-risk group and high-risk group were 
40.5 and 5.9 %, respectively (P < 0.05) (Fig. 3).Fig. 1  Overall survival (OS) curve for all the APC patients
Fig. 2  Overall survival of patients according to ECOG scored (a), CA19-9 value (b), and CRP value (c)
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Discussion
The incidence of pancreatic cancer has gradually increased 
in developing countries in recent years (Ma et al. 2013). 
Several clinical trials confirmed that gemcitabine- or 
S-1-containing palliative chemotherapy possess similar 
efficacy and safety for patients with APC; nevertheless, 
the prognosis of APC patients remains dismal (Stathis and 
Moore 2010; Burris et al. 1997; Heinemann et al. 2008; 
Okusaka et al. 2008; Ueno et al. 2013; Michl and Gress 
2013). It is clinically relevant to identify the prognostic 
factors for APC patients in determination of the treatment 
strategy.
Previous studies have reported several prognostic fac-
tors related to poor outcomes for APC patients, includ-
ing elevated pretreatment levels of CA19-9 (Saad et al. 
2002; Reni et al. 2009), CRP (Haas et al. 2010; Wang 
et al. 2012; Pine et al. 2009), and LDH (Haas et al. 2010; 
Tas et al. 2001), increased ratio of neutrophil to lympho-
cyte (Xue et al. 2014), poor performance status (Tas et al. 
2013), and status of initial unresectable disease (Xue et al. 
2014). However, the prognostic factors reported were dif-
ferent in various studies. In the current study, we devised 
a convenient prognostic index model by retrospectively 
analyzing various clinicopathological factors and pre-
treatment parameters in APC patients receiving palliative 
chemotherapy. Three factors, including ECOG score of 2, 
CA19-9 levels of ≥1000 U/mL, and CRP levels ≥5 mg/L, 
were identified as independent adverse prognostic factors 
for OS in APC patients in our cohort. Creating a prognostic 
index model with these three factors, patients classified as 
low risk with this model showed significant survival ben-
efit from gemcitabine- or S-1-based chemotherapy, with a 
median survival duration of 9.9 months and 1-year survival 
rate of 40.5 %, which was much better than the patients 
categorized as high risk, with median survival duration of 
5.3 months and a 1-year survival rate of 5.9 %. Based on 
these values, palliative chemotherapy of gemcitabine- or 
S-1-containing regimen showed no significant survival ben-
efit for the patients in high-risk group. As to the low-risk 
group of patients, it should be noted that those who have 
fewer poor prognostic factors may do well even without 
chemotherapy. Nevertheless, this prognostic index model 
would help oncologists to avoid excessive medical treat-
ment for APC patients in high-risk group; meanwhile, it is 
urgent to develop novel therapeutical strategies for these 
intractable high-risk groups of APC patients.
 Previous studies have proposed various prognostic 
models for APC patients (details in Table 4). Hamada 
et al. (2014) recently designed a nomogram derived from 
analysis of their prospectively collected 531 patients 
with inoperable pancreatic cancer receiving palliative 
chemotherapy, which contained six potential prognos-
tic factors of age, sex, ECOG PS score, tumor size, 
regional lymph node metastasis, and distant metastasis 
status. This nomogram provided improved ability to pre-
dict clinical outcome for each patient with APC. Yi et al. 
(2011) devised a risk-stratified prognostic model derived 
from 298 APC patients who received gemcitabine-based 
chemotherapy, which consists of four prognostic factors, 
including serum CRP levels, albumin levels, metasta-
sis to liver, and ascites dissemination. The survival out-
comes differed remarkably according to the prognostic 
model stratification. However, only 84.9 % patients in 
their study had definite pathological diagnosis of ductal 
adenocarcinoma. Maréchal et al. (2007) also reported 
a prognostic index consists of three variables of KPS, 
weight loss, and AST for APC patients who received 
gemcitabine-containing chemotherapy. Using this index 











Fig. 3  Overall survival of patients by prognostic index risk group
1659J Cancer Res Clin Oncol (2015) 141:1653–1660 
1 3
model, patients were categorized into three groups with 
significantly different survival time. By contrast, three 
variables of ECOG score, CA19-9 levels, and CRP lev-
els identified in our prognostic index model represent the 
general condition, tumor burden, and systemic inflamma-
tory reaction of patient, respectively, making our result 
more close to clinical practice. Consistently, previous 
study has demonstrated that these three prognostic fac-
tors are significantly associated with the survival of a 
cohort of 103 consecutive patients with APC (Ueno et al. 
2000). The median OS of this cohort was 3.2 months in 
contrast to 8.8 months in this study, and about 30 % of 
the patients had died within 2 months from the beginning 
of systemic chemotherapy. This may be because patients 
with locally advanced APC were excluded from this 
study. Additionally, the chemotherapeutic regimen used 
in this cohort varied among patients, having only a few 
patients treated with gemcitabine monotherapy which 
is not consistent to current clinical practice. Because of 
the disparity of categorization criteria for the continuous 
parameters, such as CA19-9 and CRP, between studies 
(Yi et al. 2011; Maréchal et al. 2007; Ueno et al. 2000), 
universally accepted cutoff values of these parameters 
have yet established. This underscores the importance of 
conducting further study to elucidate this issue. Our data 
suggests that the cutoff value defined in this study based 
on previous studies and our clinical practice could be uti-
lized successfully to predict prognosis for APC patients. 
Obvious limitations should be addressed that the sample 
size of the current study is relatively small compared 
with other previous studies. Furthermore, the reliabil-
ity of the predictive model developed in retrospectively 
single center should be externally validated using another 
independent cohort data.
In this study, all the APC patients have received either 
gemcitabine- or S-1-based chemotherapy. Although the 
chemotherapy regimens differed among patients in our 
study, it is unlikely that the treatment regimens would influ-
ence the prognosis of patients. Ueno et al. (2013) demon-
strated in GEST study that efficacy of gemcitabine, S-1, 
or gemcitabine/S-1 combination therapy for patients with 
APC were not statistically different. In addition, previous 
meta-analysis studies (Heinemann et al. 2008) showed no 
significant improvement in OS for gemcitabine-based com-
binations over gemcitabine monotherapy. Furthermore, 
in our results of univariate analysis for different treatment 
regimens, the prognosis of patients received gemcitabine- 
or S-1-containing regimens showed no statistical difference 
(HR 1.55; 95 % CI 0.74–3.26; P = 0.245).
In conclusion, our study identified three independ-
ent adverse prognostic factors, ECOG, CA19-9, and CRP, 
in patients with APC who had received palliative chemo-
therapy. A prognostic index model calculated based on 
these factors was developed to stratify patients with low 
and high risk of poor prognosis. These readily accessible 
pretreatment parameters of patients and prognostic index 
model could assist clinicians to identify high-risk patients 
and propose individualized therapeutic approach to APC 
patients in clinical practice.
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Table 4  Published studies relating to the prognostic relevance by risk groups in APC patients
NA no reported
References n Treatment regimens Variables (cutoff value) Median overall survival time (by risk group)
Ueno et al. (2000) 103 Fluorouracil-based, gemcitabine, 





5.2 months (good prognostic group)
2.6 months (intermediate prognostic group)
1.4 months (poor prognostic group)
Glen et al. (2006) 187 NA CRP (10 mg/L)
Albumin (35 g/L)
8.0 months (GPS 0 group)
4.3 months (GPS 1 group)
2.3 months (GPS 2 group)
Maréchal et al. (2007) 99 Gemcitabine based KPS (90)
Weight loss (10 %)
AST (53 IU/ml)
356 days (A group)
212 days (B group)
80 days (C group)




10.0 months (low-risk group)
6.7 months (intermediate-risk group)
4.4 months (high-risk group)
Hamada et al. (2014) 531 Gemcitabine based Age, sex, ECOG PS, tumor size
Lymph node metastasis
Distant metastasis
17.5 months (very low-risk group)
13.7 months (low-risk group)
8.9 months (high-risk group)
5.5 months (very high-risk group)
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